Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00053508 · ClinicalTrials.gov registry record · Phase 2
Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination
A Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 274
- Enrollment target
NCT00053508: Clinical Trial Phase 2 study, sponsored by Sanofi Pasteur, a Sanofi Company.
NCT00053508 is a Phase 2 study that was terminated before completion, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 274 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (106% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00053508, a Phase 2 study, was terminated before completion, sponsored by Sanofi Pasteur, a Sanofi Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 274 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the safety and the effectiveness of a new vaccine for the prevention of the disease, smallpox.
Interventions
- BIOLOGICAL ACAM1000
- BIOLOGICAL vaccinia virus (calf lymph) smallpox vaccine: Dryvax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2002-09 |
| Est. Completion | 2003-09 |
| Phase | Phase 2 |
Why NCT00053508 stopped before completion
NCT00053508 is an interventional study that assigns participants to a tested intervention. The registered 274 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (106% higher).
The record links to 0 conditions, and to 2 interventions - of which ACAM1000 is the first listed.
NCT00053508 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00053508 about?
NCT00053508 is a clinical study titled "Dose Safety, Tolerability, and Immunogenicity of a New Smallpox Vaccine in Adults Without Previous Smallpox Vaccination". The purpose of this study is to examine the safety and the effectiveness of a new vaccine for the prevention of the disease, smallpox.
What is the current status of trial NCT00053508?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 274 participants. The study started on 2002-09. Estimated completion is 2003-09.
What interventions are being tested in trial NCT00053508?
The interventions under investigation include: ACAM1000 (BIOLOGICAL), vaccinia virus (calf lymph) smallpox vaccine: Dryvax (BIOLOGICAL).
Who is sponsoring clinical trial NCT00053508?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00053508's enrollment target sits among peer trials
274 203rd of 2000 higher than 1,797 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03808922 · 274 participants · Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study
- NCT04573504 · 274 participants · Phase 4
Antibiotics for Severe Perineal Laceration to Prevent Infection Following Repair
- NCT05289557 · 274 participants · Phase 3
The Efficacy and Safety of Bonjesta® for Nausea and Vomiting of Pregnancy in Pregnant Adolescents
- NCT05952583 · 274 participants
Selective Fetal Growth Restriction in Monochorionic Twins - an International Investigation
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia